FDA panel backs Merck's Vytorin in predialysis CKD, but rejects dialysis use
This article was originally published in Scrip
Executive Summary
Merck could be the first company to market a drug in the US specifically indicated to reduce major cardiovascular events in patients with chronic kidney disease (CKD) if the US FDA takes the advice of its panel of outside expert advisers, which unanimously backed the expanded use of Vytorin (ezetimibe and simvastatin) at the 10/20mg dose as a treatment for that population not on dialysis.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.